SCHEMBL19084638

SCHEMBL19084638

CCN(c1cccc(C(=O)NCc2ccccc2Cl)c1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.68
HDAC8 Q9BY41 3/20 0.58
HDAC3 O15379 2/20 0.58
HDAC11 Q96DB2 2/20 0.58
HDAC6 Q9UBN7 2/20 0.58
LMNA P02545 3/20 0.57
MAPT P10636 3/20 0.57
ALDH1A1 P00352 3/20 0.57
KMT2A Q03164 3/20 0.57
HTT P42858 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
KDM4E B2RXH2 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
DDR1 Q08345 5/20 0.54
GAA P10253 2/20 0.49
MEN1 O00255 2/20 0.48
RORC P51449 1/20 0.48
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19065139 0.83 HDAC8 (0.52) TP53HDAC8HDAC3HDAC11HDAC6
SCHEMBL19065063 0.83 HDAC8 (0.51) TP53HDAC8HDAC3HDAC11HDAC6
SCHEMBL19084657 0.81 HDAC8 (0.65) HDAC8HDAC3HDAC11HDAC6LMNA
SCHEMBL19065088 0.80 HDAC3 (0.52) TP53HDAC8HDAC3HDAC11HDAC6
SCHEMBL19084656 0.80 MEN1 (0.69) HDAC8HDAC3HDAC11HDAC6LMNA
SCHEMBL19065140 0.80 HDAC8 (0.66) HDAC8HDAC3HDAC11HDAC6LMNA
SCHEMBL19084636 0.79 HDAC8 (0.66) HDAC8HDAC3HDAC11HDAC6LMNA
SCHEMBL19065086 0.78 HDAC3 (0.49) HDAC8HDAC3HDAC11HDAC6LMNA
SCHEMBL19065148 0.76 HDAC8 (0.52) HDAC8HDAC3HDAC11HDAC6LMNA
SCHEMBL19084700 0.74 HDAC8 (0.59) HDAC8HDAC3HDAC11HDAC6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10189777-B2 Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-01-29 US disclosed
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-07-06 US disclosed
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10189777-B2 Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease RORC, RORB, RORA TP53 560/4885HDAC8 1368/4885HDAC3 1051/4885
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE RORB, RORA, RORC TP53 592/4885HDAC8 1717/4885HDAC3 1493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.